重庆医学2017，Vol.46Issue(21)：2914-2916,2920,4.DOI:10.3969/j.issn.1671-8348.2017.21.010
慢性阻塞性肺疾病患者幽门螺杆菌耐药状况研究
Study on drug resistance status of Helicobacter pylori in patients with chronic obstructive pulmonary disease
摘要
Abstract
Objective To study the resistance status of helicobacter pylori (HP) to commonly used antibacterial drugs as well as clinical effects of quadruple therapy in the patients with chronic obstructive pulmonary disease (COPD) infected by Hp.Methods A total of 180 cases of patients with Hp infection in the inpatient department and outpatient department of our hospital from August 2012 to December 2014 were collected,including 90 cases of COPD (COPD group) and 90 cases of non-COPD (control group).The gastric antrum mucosal tissues in all cases were taken for conducting Hp culture and identification.The resistance situation to clarithromycin,metronidazole,amoxicillin,levofloxacin and furazolidone in each group was observed.In addition,the two groups were equally divided into subgroup A,B and C according to different medication schemes:which were given 3 kinds of quadruple medication scheme containing amoxicillin and clarithromycin (group A),amoxicillin and levofloxacin (group B) and amoxicillin and furazolidone (group C).Then the clinical effects were compared.Results The resistance rate of infected Hp strains to clarithromycin in the control group was 21.11%;which to metronidazole was 55.56%;which to amoxicillin was 3.33%;which to levofloxacin was 5.56%,while which in the COPD group were in turn 26.67%,57.78%,7.78% and 16.67% respectively.No strain was found to be resistant to furazolidone in the two groups.There was statistically significant difference in the resistance to levofloxacin and double antibiotic resistance between the two groups (P<0.05).The eradication rates for using 3 kinds of quadruple therapy in 3 subgroups of control group were 90.0% in the group A,96.7% in the group B and 100.0% in the group C,while which in the COPD group were 86.7%,80.0% and 96.7% respectively;the Hp eradication rate for adopting the group B scheme had statistical difference between the two groups (P<0.05).Conclusion The resistance rate of COPD patient affected by Hp to levofloxacin has an increasing trend,so its use should be cautious.The quadruple scheme containing amoxicillin+furazolidone can serve as the preferred scheme for the initial Hp eradication therapy in COPD patients affected by Hp.关键词
螺杆菌,幽门/肺疾病,慢性阻塞性/耐药/四联疗法Key words
Helicobacter pylori/pulmonary disease,chronic obstructive/drug resistance/quadruple therapy分类
医药卫生引用本文复制引用
周钢,胡毅,赵正中..慢性阻塞性肺疾病患者幽门螺杆菌耐药状况研究[J].重庆医学,2017,46(21):2914-2916,2920,4.基金项目
重庆市卫生局医学科研计划面上项目(2011-2-450). （2011-2-450）
